Author Archive

Professor Pugatch lead a discussion of Swedish life sciences stakeholders on how the EU is doing in the global life sciences innovation investment race

Posted by:

Yesterday Professor Pugatch spoke to an audience of Swedish life sciences stakeholders on the EU’s capacity to compete in the global life sciences innovation race, at an event organized in Stockholm by Bayer Sweden in collaboration with the Karolinska Institute Holding.

Professor Pugatch provided an evidence-based analysis of the EU’s performance in attracting life sciences investment as compared to the US and emerging Asian players, and reflected on the ongoing shifts in life sciences innovation capacities at the global level.

In which ...

Continue Reading →
0

Generating biopharmaceutical Competitiveness and Investment in emerging markets – Insights from the ground up with the 2019 Emerging Markets BCI survey

Posted by:

In the global competition for biopharmaceutical investment policy environments either enable or hinder an economy’s capacity to compete. Today who is winning this race and who is trailing? What aspects of individual economies’ environments are providing momentum and what is holding them back? And ultimately, how can governments improve their competitiveness and secure a larger piece of global biomedical investment?

To answer these questions we turned to biopharmaceutical country executives, who are at the forefront of understanding how different aspects of ...

Continue Reading →
0

Pugatch Consilium is releasing the sixth edition of the Building the Bioeconomy

Posted by:

Pugatch Consilium is today releasing the sixth edition of the Building the Bioeconomy, a series of papers commissioned by the Biotechnology Industry Organization. Since 2013, the series has taken the pulse of biotechnology policies in the main economies worldwide, and has shown that policy choices are key determinants of success in growing biotechnology sectors.
This year’s edition adds to the analysis eleven countries, further increasing the geographic and economic diversity of the countries sampled. Yet, the findings of the report ...

Continue Reading →
0

New Pugatch Consilium Study Shows How Countries Can Develop Biotech Industry

Posted by:

A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Continue Reading →
0

Why IP Incentives Matter for Life Sciences Innovation – In Europe and Beyond

Posted by:

Why IP incentives matter for life sciences innovation – In Europe and Beyond

Pugatch Consilium is today releasing a new report – A Critical Incentive – Not a Barrier! How IP incentives spur biopharmaceutical innovation and the creation of new health technologies.

This report examines the importance of IP based incentives to biopharmaceutical innovation and the development of new medicines and medical technologies.

This analysis could not be more timely. In Europe, for example, the EU Commission is seriously considering ways to ...

Continue Reading →
0

Debunking the IP and Access to Medicines Myth Once and For All

Posted by:

Pugatch Consilium is today releasing the report Unlocking Global Health Strengthening Availability of Essential Medicines by Enhancing Healthcare Financing and Reducing Supply Chain Costs.

This report examines a common misperception in the international community: that patents and IP incentives block access to medicines.

 

An age-old debate: Patents and access

Discussions over the impact – positive or negative; rarely neutral – that IP rights have had and continue to have on the creation and dissemination of new ideas and commercial products is ...

Continue Reading →
0

To SPC or not to SPC…

Posted by:

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Continue Reading →
0

Unintended Consequences

Posted by:

Pugatch Consilium releases new study on the negative economic consequences of an SPC export exemption in Europe

Today Pugatch Consilium releases UNINTENDED CONSEQUENCES: How introducing a manufacturing and export exemption to supplementary protection certificates would weaken global standards of IP protection and result in direct losses to Europe’s research-based biopharmaceutical industry.

The study (which is also available via the Social Science Research Network, SSRN) models the economic impact an SPC manufacturing and export exemption would have on the European and global research-based ...

Continue Reading →
0

Building a Bioeconomy: A how-to guide

Posted by:

New study shows how countries can succeed in developing and building their biotech capabilities

A new study by international research consultancy Pugatch Consilium (commissioned by the Biotechnology Industry Organization) examines those national innovation strategies, policies and best practices that have been successful in creating an environment in which biotechnologies and biotechnological innovation can flourish.

2017 marks the fourth edition of the Building the Bioeconomy series of papers examining national biotechnology industrial policies. This year’s edition includes 26 countries from all major regions ...

Continue Reading →
0

Professor Meir Pugatch and U.S. Chamber of Commerce President Tom Donohue launch new fifth edition of the U.S. Chamber of Commerce’s International IP Index

Posted by:

Professor Meir Pugatch spoke together with Tom Donohue (President and CEO of the U.S. Chamber of Commerce), David Hirschmann (President and CEO of the U.S. Chamber of Commerce Global Intellectual Property Center) and former Director of the United States Patent and Trademark Office, David Kappos, at the launch of the fifth edition of the U.S. Chamber’s International IP Index in Washington D.C earlier this week.

Continue Reading →

0
Page 1 of 5 12345